Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles.
Meade RM, Fairlie DP, Mason JM. · 2019
Read Alpha-synuclein structure and Parkinson's disease - lessons and emerging principles. by Meade RM, Fairlie DP, Mason JM. (2019) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/europmc-pmc6647174.txt.
Introduction
Meade and co-authors rethink alpha-synuclein structure and its role in Parkinson's disease. Their review appears in Molecular Neurodegeneration. The protein forms the Lewy bodies that mark synuclein diseases. These include Parkinson's, Lewy body dementia, and multiple system atrophy. Each disease shows a distinct pattern of deposits. New structural methods have changed the picture fast. Solid-state NMR and cryo-electron microscopy resolved fibril shapes. Native forms of the protein are also clearer now.
The authors reinterpret older literature against these structures. They ask how shape may dictate pathology. Different folds could explain different diseases. The synthesis points to where the field should head. Structure-guided ideas for diagnosis and therapy close the piece.
Catalog record
| CREATOR | Meade RM, Fairlie DP, Mason JM. |
|---|---|
| YEAR | 2019 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 73 KB |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |
Browse the full library · About the Tower of Babel
Full text
The opening of the work, from the library's hosted text:
Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles By Richard M Meade, David P Fairlie, Jody M Mason Published in: Molecular Neurodegeneration DOI: 10.1186/s13024-019-0329-1 ABSTRACT Abstract Alpha-synuclein (αS) is the major constituent of Lewy bodies and a pathogenic hallmark of all synucleinopathathies, including Parkinson’s disease (PD), dementia with Lewy bodies (DLB), and multiple system atrophy (MSA). All diseases are determined by αS aggregate deposition but can be separated into distinct pathological phenotypes and diagnostic criteria. Here we attempt to reinterpret the literature, particularly in terms of how αS structure may relate to pathology. We do so in the context of a rapidly evolving field, taking into account newly revealed structural information on both native and pathogenic forms of the αS protein, including recent solid state NMR and cryoEM fibril structures. We discuss how these new findings impact on current understanding of αS and PD, and where this information may direct the field. Keywords: Alpha-synuclein, Amyloid, Oligomers, Parkinson’s disease, Protein-protein interactions, CryoEM BACKGROUND Parkinson’s Disease (PD) is a progressive neurodegenerative disease, which accounts for approximately 15% of all dementia cases [1], and is the second most common form of neurodegeneration to Alzheimer’s disease [2]. The disease has a mean onset of 55 years old and exhibits both physical and neuropsychiatric symptoms. The physical symptoms include slow imprecise movements (bradykinesia), tremors at rest, rigidity, facial paucity (hypomimia), shuffling gait, difficulty walking, freezing and postural instability [2]. The neuropsychiatric symptoms, which occur at later stages of the disease, manifest as cognitive defects, specifically slowness, disrupted sleep, and sensory disturbances, leading to suffers becoming passive and withdrawn [2]. PD is thought to be largely caused by the death of dopaminergic neurons in the substantia nigra pars compacta, located in the basal ganglia of the brain. This region of the brain is involved in coordinating movement, sending signals down the spinal cord to control muscle contraction, meaning that damage to this region can compromise signalling, leading to the physical symptoms of PD. A wide range of both environmental and genetic risk factors have been implicated in the pathogenesis of PD [3]. Environmental risk factors include pesticides (specifically organochlorines) [4] and ambient air pollution [5]. Interestingly, tobacco [6], coffee [7], black tea [8], and a few pharmaceuticals including statins [9], calcium channel blockers [10] and ibuprofen [11], have shown some evidence of neuroprotective properties in a few studies. Autosomal dominant risk factors implicated with PD were first found in the SNCA gene that encodes αS, the primary component of Lewy bodies that are characteristic of all synucleinopathies. This will be discussed in detail and is the main focus of this review. It is worth noting that there are a number of other autosomal dominant and recessive risk factors implicated in PD, some of which occur upstream of the toxicity caused by αS. Other autosomal dominant mutations are found in the Leucine rich repeat Kinase 2 (LRRK2) domain, accounting for 4% of familial PD [12], in the vascular protein sorting 35 (VPS35) gene [13], accounting for 1% of familial PD and in the CHCHD2 [14] and eIF4G1 [15] genes. Recessive genes implicated in familial PD are Parkin [16], PTEN-induced putative kinase 1 (PINK1) [17], and Daisuke-Junko-1 (DJ1) [18] genes. These genes are upstream mutations which appear to increase αS toxicity, suggesting that further advances in understanding αS structure and function may be crucial to understanding and ultimately treating PD. PD is strongly associated with the appearance of dopaminergic neuronal cytoplasmic inclusions called Lewy bodies. These are the leading pathogenic hallmarks in brain biopsies of PD patients, and are not present in healthy individuals. In 1997 Lewy body inclusions were shown to contain aggregates of αS [19], a 140 amino acid protein which has consequently been implicated as the likely cause of familial PD [20–22]. Further evidence is provided by the fact that duplication, triplication and autosomal dominant missense mutations in the SNCA gene lead to early onset forms of PD. It is now believed that the misfolding and subsequent aggregation of αS is a primary cause of dopaminergic degradation in PD. This is confounded by a rapidly ageing global population, correlating with an increasing number of sporadic cases of PD. In the United Kingdom alone it is believed that about 0.2% of the population are living with PD, affecting an estimated 127,000 people, and currently costing the NHS approximately £212 million per year [23]. This highlights the importance of discovering new methods to diagnose, treat and especially prevent neurodegeneration associated with PD and related synucleinopathies, and to better understand their pathogenesis. Effective strategies for preventing or reversing αS aggregation and neurotoxicity are urgently needed to avoid an exponential increase in disease with an ageing population. Recent solid state NMR and cryoEM fibril structures have brought new structural insights to the folding and formation of both native and pathogenic conformations of the αS protein [24–27]. α-Synuclein: native structure and function Despite considerable effort, the precise native structure of αS is still poorly defined. It has been variously described as intrinsically disordered [28, 29], helical [30, 31], or a combination of the two [32]. A helix-rich structure has been shown to be more readily populated in the presence of phospholipid membranes [33, 34] (Fig. 1), offering one possible insight towards the functional role of the protein. [Figure: Change in Circular Dichroism (CD) signal in the far UV caused by the binding of αS to an excess of DMPS vesicles. This demonstrates a shift from a random coil structure in the absence of lipid vesicles (green), towards an alpha-helical secondary structure in the presence of DMPS lipid vesicles (red). Meade et. al. unpublished data reproducing data from Galvagnion et al. [34]] Identifying the precise native state(s) of αS has certainly been hampered by the lack of knowledge of a clear function for the protein, its binding partners, or specific post-translational modifications (see below). The majority of studies have failed to take these variables into account. A wide range of publications have sought to interrogate the structure in a variety of different buffer conditions, including variations in salt, pH and lipid composition [35]. More recently, others have studied different modifications to the protein composition (e.g. phosphorylation, glycation, glycosylation, acetylation) and possible effects on protein structure and function [29, 36, 37]. Some groups have studied protein expression and aggregation in disease-relevant mammalian model systems to identify and understand possible roles for PTMs and the local environment on pathology. A current consensus is that αS functions to promote membrane curvature, thereby contributing to synaptic trafficking and vesicle budding [38, 39]. This may be important given the association of αS with presynaptic terminal SNARE complexes [40], and suggests a potential role for αS in modulating dopamine release. This in turn has led to a number of studies investigating the transmission of the protein via synaptic terminals. Additional evidence lends support to a ‘prion-like’ hypothesis, whereby oligomeric αS can migrate between neurons to propagate formation of Lewy bodies throughout the substantia nigra and into extranigral regions. In particular, Bartels et al [30] and Wang et al [31] independently provided evidence that αS is able to fold into a stable helical structure by associating to form homotetrameric structures. This result was controversial as it